The high sensitivity and specificity indicate SleepCheck can potential be classified as a diagnostic tool (unlike Drowzle which is the only competitor with similar technology but has very low specificity of 63% and can only detect AHI>=15) which management indicate they are planning later but right now best to get the product out to the population and earn some revenue.
- Forums
- ASX - By Stock
- RAP
- Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic
Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic, page-140
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online